ABCL · AbCellera Biologics Inc.

Abcellera Biologics Inc Is A Clinical-Stage Biotechnology Company Focused On Discovering And Developing First-In-Class Antibody Medicines For Indications With High Unmet Medical Need. It Has Built A Platform For Advancing Antibody Drug Programs That The Company Believes Provides It With A Competitive Advantage In Addressing Challenging, High-Value Targets Such As Complex Transmembrane Proteins And Novel Modalities, Including Multispecifics And Antibody-Drug Conjugates. Organisation'S Pipeline Includes Two Drug Candidates In Clinical Development, Two Development Candidates In Investigational New Drug (Ind/Clinical Trial Application (Cta)-Enabling Activities, And More Than 20 Active Discovery Programs Across Multiple Modalities And Indications.